Treatment with the lowest dose of TH1902 or with anti-PD-L1 alone yielded slight but not significant (p = 0.1394 and 0.1787, respectively) tumor growth inhibition (TGI) compared to that in vehicle-treated animals; tumor sizes at 10 days following treatment start were halved similarly to those in vehicle-treated animals, with a median survival of either 14 (TH1902 4.37 mg/kg/wk and anti-PD-L1, both p = 0.0521) or 11.5 (vehicle) days. This evidence concerns the gene CD274 and neoplasm.